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The current research was performed to evaluate the effects of omega-3 fatty acids and vitamin E co-
supplementation on clinical signs and metabolic status in people with Parkinson's disease (PD). This
randomized double-blind placebo-controlled clinical trial was conducted in 60 patients with PD. Par-
ticipants were randomly assigned into two groups to receive either 1000 mg omega-3 fatty acids from
ﬂaxseed oil plus 400 IU vitamin E supplements (n ¼ 30) or placebo (n ¼ 30) for 12 weeks. Uniﬁed
Parkinson's disease rating stage (UPDRS) were recorded at baseline and the after 3-month intervention.
After 12 weeks' intervention, compared with the placebo, omega-3 fatty acids and vitamin E co-
supplementation led to a signiﬁcant improve in UPDRS (3.3 ± 10.0 vs. þ4.4 ± 14.9, P ¼ 0.02).
Furthermore, co-supplementation decreased high-sensitivity C-reactive protein (hs-CRP) (0.3 ± 0.6
vs. þ0.3 ± 0.3 mg/mL, P < 0.001), and increased total antioxidant capacity (TAC) (þ65.2 ± 68.7
vs. þ16 ± 52.4 mmol/L, P ¼ 0.003) and glutathione (GSH) concentrations (þ41.4 ± 80.6
vs. 19.6 ± 55.9 mmol/L, P ¼ 0.001) compared with the placebo. Additionally, co-supplementation
meaningfully decreased insulin (2.1 ± 4.9 vs. þ1.4 ± 6.2 mIU/mL, P ¼ 0.01), homeostasis model of
assessment-estimated insulin resistance (0.7 ± 1.8 vs.þ0.3 ± 1.6, P ¼ 0.02) and Beta cell function
(5.9 ± 13.9 vs. þ5.7 ± 25.5, P ¼ 0.03), and increased quantitative insulin sensitivity check index
(þ0.009 ± 0.02 vs. 0.006 ± 0.03, P ¼ 0.03) compared with the placebo. Overall, our study demonstrated
that omega-3 fatty acids and vitamin E co-supplementation in people with PD had favorable effects on
UPDRS, hs-CRP, TAC, GSH and markers of insulin metabolism.
© 2017 Elsevier Ltd. All rights reserved.1. Introduction
Parkinson's disease (PD) is a progressive disorder inﬂuencing
more than 3% of subjects with age over 75 years (de Lau and
Breteler, 2006). Prior studies have demonstrated that the patho-
logical marking of PD is the intraneuronal reposition of uncommon
ﬁlamentous inclusions containing phosphorylated a-synuclein(phosaSYN) (Jellinger, 2003; Braak and Del Tredici, 2008). In
addition, increased oxidative stress involves early events associated
with dopaminergic neuronal degeneration in PD (Lv et al., 2015).
Neuroendocrine abnormalities including glucose intolerance, in-
sulin resistance and bone metabolism, and body weight changes
are also common in PD (De Pablo-Fernandez et al., 2017).
Previous reports have indicated that omega-3 fatty acids deﬁ-
ciency can reduce the nigrostriatal system's ability to maintain
homeostasis under oxidative conditions, which may increase the
risk of PD (Fabelo et al., 2011; Cardoso et al., 2014). Furthermore,
few researchers have exhibited that concentrations of vitamin E
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2003; Fukushima et al., 2011). Our previous study among gesta-
tional diabetes (GDM) have demonstrated that co-supplementation
with 1000 mg omega-3 fatty acids and 400 IU vitamin E daily for 6
weeks increased total antioxidant capacity (TAC) and nitric oxide
(NO), and decreased malondialdehyde (MDA) values, but unaltered
glutathione (GSH) and high-sensitivity C-reactive protein (hs-CRP)
levels (Jamilian et al., 2016). However, no signiﬁcant effect in
indices of oxidative stress and/or inﬂammation was seen following
supplementation with omega-3 fatty acids in healthy adults for 4
weeks (Cunnane et al., 1995) and vitamin E in hemodialysis (HD)
people for 8 weeks (Ahmadi et al., 2013).
Omega-3 and vitamin E may result in improved clinical signs,
indices of inﬂammation and oxidative stress, and metabolic status
through their effects on modiﬁcations in the dopamine metabolism
(Cardoso et al., 2014), decreased inﬂammatory markers (Zhuang
et al., 2013), reducing production of reactive oxygen species (ROS)
in the mitochondria (Capo et al., 2015) and improved antioxidant
defense (Gupta et al., 2011). However, whether omega-3 and
vitamin E co-supplementation have direct beneﬁts on clinical signs,
biomarkers of inﬂammation and oxidative stress, and metabolic
parameters in people with PD has to date not been evaluated. This
intervention was, therefore, performed to determine the effects of
omega-3 and vitamin E co-supplementation on clinical signs,
indices of inﬂammation and oxidative stress, and metabolic pa-
rameters in people with PD.
2. Materials and methods
2.1. Participants
This treatment, registered in the Iranianwebsite for registration
of clinical trials (http://www.irct.ir: IRCT201604035623N73), was a
randomized, double-blind, placebo-controlled clinical trial that was
done among people with PD aged 50e80 years old diagnosed ac-
cording to clinical diagnostic criteria of the UK PD Society Brain
Bank (Hughes et al., 1992) referred to the Shahid Beheshti Clinic in
Kashan, Iran, between March 2016 and June 2016. The diagnosis of
PD was conﬁrmed by 2 neurologists. Exclusion criteria were pa-
tients who were already taking omega-3 and/or vitamin E, had
depression and had severe psychosis.
2.2. Study design
Subjects were randomly divided into two groups to intake either
1000 mg omega-3 fatty acids from ﬂaxseed oil plus 400 IU vitamin
E supplements (n¼ 30: 21males and 9 females) or placebo (n¼ 30:
21 males and 9 females) for 12 weeks. Subjects were requested not
to change their ordinary physical activity during the 12-week trial.
All subjects completed 3-day food records and three physical ac-
tivity records at weeks 0, 3, 6, 9 and 12 of the intervention. Daily
macro- andmicro-nutrient intakes were analyzed by nutritionist IV
software (First Databank, San Bruno, CA).
2.3. Treatment adherence
The use of supplements and placebos during the study was
checked by asking participants to return themedication containers.
To increase compliance, all participants received brief daily cell
phone reminders to intake the supplements.
2.4. Assessment of anthropometric measures
Weight and height of subjects were determined in a fasting
status using a standard scale (Seca, Hamburg, Germany) at week0 and after the 12-week treatment. BMI was calculated as weight in
kg divided by height in meters squared.
2.5. Assessment of outcomes
The primary outcomes variables were Uniﬁed Parkinson's Dis-
ease Rating Stage (UPDRS) and inﬂammatory markers in the cur-
rent study. The secondary outcomes variables were biomarkers of
oxidative stress and metabolic proﬁles.
2.6. Clinical evaluation at entry
To assess clinical signs, UPDRS total score as well as 4 subscores
(part I: nonmotor experiences of daily living; part II: motor expe-
riences of daily living; part III: motor examination; and part IV:
motor complications) were used (Goetz et al., 2008).
2.7. Assessment of outcomes
Twelve-hour fasting blood samples were collected at baseline
and after the 12-week intervention at Kashan reference laboratory.
Serum hs-CRP values were assessed using commercial ELISA kit
(LDN, Nordhorn, Germany) with the intra- and inter-assay coefﬁ-
cient variances (CVs) 3.7 and 5.6%, respectively. Plasma nitric oxide
(NO) levels were determined by the Giess method (Tatsch et al.,
2011). Plasma total antioxidant capacity (TAC) using the method
of ferric reducing antioxidant power method developed by Benzie
and Strain (Benzie and Strain, 1996), GSH by the method of Beutler
et al (Beutler and Gelbart, 1985) and malondialdehyde (MDA)
values using the thiobarbituric acid reactive substance method
(Janero,1990) were quantiﬁed. All inter- and intra-assay CVs for NO,
TAC, GSH and MDA were lower than 5%. To assess fasting plasma
glucose (FPG), serum triglycerides, VLDL-, total-, LDL- and HDL-
cholesterol fractions, we used available kits (Pars Azmun, Tehran,
Iran). All inter- and intra-assay CVs for FPG and lipid fractions were
lower than 5%. Serum insulin values were assessed using ELISA kit
(Monobind, California, USA) with the intra- and inter-assay CVs 3.2
and 5.1%, respectively. HOMA-IR, homeostatic model assessment
for B-cell function (HOMA-B) and the quantitative insulin sensi-
tivity check index (QUICKI) were calculated according to suggested
formulas (Pisprasert et al., 2013).
2.8. Sample size
On the basis of sample size formula suggested for randomized
clinical trials, considering the type I error of 5% (a ¼ 0.05) and type
II error of 20% (b ¼ 0.20; Power ¼ 80%) and serum hs-CRP values as
key variable (Asemi et al., 2016), we used 2.5 as SD and 2.1 mg/mL as
the change in mean (d) of serum hs-CRP levels as main variable.
Based on this, we needed 25 subjects in each group. Assuming 5
dropouts in each group, the ﬁnal sample size was determined to be
30 subjects per group.
2.9. Randomization
Randomization assignment was done using computer-
generated random numbers as blindness by a trained staff at the
clinic.
2.10. Statistical methods
To determine whether the study variables were normally
distributed or not, we applied the Kolmogrov-Smirnov test. Ana-
lyses were performed based on an intention-to-treat (ITT) princi-
ple. To detect differences in anthropometric measures as well as in
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used Student's t-test to independent samples. Differences in pro-
portions were evaluated by Chi square test. To evaluate the effects
of omega-3 fatty acids and vitamin E co-supplementation on
UPDRS, biomarkers of inﬂammation and oxidative stress, and
metabolic proﬁles, we used one-way repeated measures analysis of
variance. Adjustment for changes in baseline values of biochemical
variables, age and BMI at baseline was performed by analysis of
covariance (ANCOVA) using general linear models. The P-value
of<0.05 were considered statistically signiﬁcant. All statistical an-
alyses used the Statistical Package for Social Science version 18
(SPSS Inc., Chicago, Illinois, USA).3. Results
Among subjects in the supplements and placebo groups, 3
people [withdrawn (n ¼ 3)] were excluded (Fig. 1). In the end, 54
subjects [omega-3 and vitamin E (n ¼ 27) and placebo (n ¼ 27)]
completed the trial. However, as the analysis was based on the ITT
principle, all 60 people (30 in each group) were included in the ﬁnal
analysis.
Distribution of gender, disease severity, mean age, height,
weight and BMI as well as METs at week 0 and week 12 were not
different between the two groups (Table 1).
Based on the 3-day dietary records obtained at week 0,
throughout of the trial and week 12, we found no signiﬁcant dif-
ference in mean macro- and micronutrient intakes between the
two groups (Data not shown).
After 12 weeks’ intervention, compared with the placebo,
omega-3 and vitamin E co-supplementation led to a signiﬁcant
improvement in UPDRS (3.3 ± 10.0 vs. þ4.4 ± 14.9, P ¼ 0.02)
(Table 2). Furthermore, co-supplementation decreased high-
sensitivity C-reactive protein (hs-CRP) (0.3 ± 0.6
vs. þ0.3 ± 0.3 mg/mL, P < 0.001), and increased TAC (þ65.2 ± 68.7
vs. þ16 ± 52.4 mmol/L, P ¼ 0.003) and GSH concentrations
(þ41.4 ± 80.6 vs. 19.6 ± 55.9 mmol/L, P ¼ 0.001) compared with
the placebo. Additionally, co-supplementation meaningfullyRandomized (n=
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Fig. 1. Summary odecreased insulin (2.1 ± 4.9 vs. þ1.4 ± 6.2 mIU/mL, P ¼ 0.01),
HOMA-IR (0.7 ± 1.8 vs.þ0.3 ± 1.6, P ¼ 0.02) and HOMA-B
(5.9 ± 13.9 vs. þ5.7 ± 25.5, P ¼ 0.03), and increased QUICKI
(þ0.009 ± 0.02 vs. 0.006 ± 0.03, P ¼ 0.03) compared with the
placebo. We did not see any signiﬁcant change on other indices of
inﬂammation, oxidative stress, FPG and lipid proﬁles following
intake of omega-3 plus vitamin E.
Baseline levels of plasma TAC were different between the two
groups. Therefore, we controlled the analyses for the baseline
values of biochemical parameters, age and baseline BMI. However,
after this adjustment, QUICKI (P ¼ 0.05) became non-signiﬁcant,
while plasma MDA levels (P ¼ 0.02) became signiﬁcant, and other
ﬁndings did not alter (Table 3).4. Discussion
In this research, we evaluated the effects of omega-3 and
vitamin E co-supplementation on clinical signs and metabolic
indices in people with PD. We found that omega-3 fatty acids and
vitamin E co-supplementation for 12 weeks in patients with PD had
favorable effects on UPDRS, serum hs-CRP, plasma TAC, GSH and
markers of insulin metabolism, but did not affect other indices of
inﬂammation and oxidative stress, and lipid proﬁles. To our
knowledge, this trial is the ﬁrst to have assessed the effects of
omega-3 and vitamin E co-supplementation on clinical signs and
metabolic indices in people with PD. It must be kept mind that
biomarkers of inﬂammation or oxidative stress can be different in
the early and late stages of PD, and biomarkers such as MDA, CRP,
NO, and antioxidant resources are differentially affected (de Farias
et al., 2016), therefore, all patients were matched for disease
severity based on UPDRS and gender.
We found that omega-3 and vitamin E co-supplementation in
people with PD for 12 weeks improved UPDRS compared with the
placebo. However, data on the effects of omega-3 and vitamin E co-
supplementation on UPDRS in human studies are scarce. In a study
by Tanriover et al. (2010) it was observed that docosahexaenoic acid
(DHA) increased glial cell-derived neurotrophic factor and60)
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Table 1
General characteristics of study participants.a
Placebo group
(n ¼ 30)
Omega-3 plus vitamin E group
(n ¼ 30)
Pb
Gender (%)
Male 21 (70.0) 21 (70.0) 1.00c
Female 9 (30.0) 9 (30.0)
Disease severity (%)
Mild 6 (20.0) 5 (16.7) 0.73c
Moderate 24 (80.0) 25 (83.3)
Age (y) 66.0 ± 10.4 63.9 ± 8.9 0.38
Height (cm) 163.1 ± 5.9 163.5 ± 5.4 0.78
Weight at study baseline (kg) 66.6 ± 7.6 68.3 ± 12.9 0.53
Weight at end-of-trial (kg) 66.3 ± 6.9 68.7 ± 12.5 0.34
Weight change (kg) 0.4 ± 2.2 0.4 ± 0.9 0.08
BMI at study baseline (kg/m2) 25.1 ± 3.1 25.6 ± 4.7 0.65
BMI at end-of-trial (kg/m2) 25.0 ± 2.8 25.7 ± 4.6 0.44
BMI change (kg/m2) 0.1 ± 0.8 0.1 ± 0.3 0.07
a Data are means± SDs.
b Obtained from independent t-test.
c Obtained from Pearson Chi-square test.
Table 2
Uniﬁed Parkinson's disease rating stage, biomarkers of inﬂammation and oxidative stress, and metabolic proﬁles at baseline and after the 3-month intervention in patients
with Parkinson's disease that received either omega-3 fatty acids plus vitamin E or placebo.a
Placebo group (n ¼ 30) Omega-3 and vitamin E group (n ¼ 30) Pb
Baseline End-of-trial Change Baseline End-of-trial Change
UPDRS total (0e195) 46.1 ± 18.0 50.5 ± 17.1 4.4 ± 14.9 47.4 ± 16.6 44.1 ± 14.7 3.3 ± 10.0 0.02
hs-CRP (mg/mL) 3.4 ± 1.5 3.7 ± 1.7 0.3 ± 0.3 3.7 ± 1.7 3.4 ± 1.9 0.3 ± 0.6 <0.001
NO (mmol/L) 47.5 ± 3.0 51.3 ± 5.5 3.7 ± 5.5 48.1 ± 4.1 52.3 ± 5.1 4.2 ± 4.7 0.72
TAC (mmol/L) 735.9 ± 79.7 751.9 ± 85.9 16.0 ± 52.4 819.8 ± 26.1 885.0 ± 60.4 65.2 ± 68.7 0.003
GSH (mmol/L) 603.3 ± 77.5 583.7 ± 55.8 19.6 ± 55.9 591.1 ± 59.6 632.5 ± 85.9 41.4 ± 80.6 0.001
MDA (mmol/L) 2.3 ± 0.4 2.3 ± 0.3 0.009 ± 0.4 2.3 ± 0.4 2.2 ± 0.2 0.1 ± 0.4 0.18
FPG (mg/dL) 101.8 ± 40.8 100.3 ± 42.3 1.5 ± 13.7 105.0 ± 38.1 94.0 ± 38.0 11.0 ± 22.4 0.05
Insulin (mIU/mL) 10.1 ± 6.1 11.5 ± 5.0 1.4 ± 6.2 11.2 ± 6.0 9.1 ± 4.6 2.1 ± 4.9 0.01
HOMA-IR 2.8 ± 3.0 3.1 ± 2.5 0.3 ± 1.6 3.0 ± 2.2 2.3 ± 1.3 0.7 ± 1.8 0.02
HOMA-B 33.7 ± 19.2 39.4 ± 18.9 5.7 ± 25.5 37.0 ± 20.7 31.1 ± 19.8 5.9 ± 13.9 0.03
QUICKI 0.34 ± 0.03 0.33 ± 0.03 0.006 ± 0.03 0.33 ± 0.03 0.34 ± 0.03 0.009 ± 0.02 0.03
Triglycerides (mg/dL) 116.3 ± 45.0 118.4 ± 55.5 2.1 ± 4.9 106.3 ± 38.6 106.7 ± 37.3 0.4 ± 46.3 0.85
VLDL-cholesterol (mg/dL) 23.2 ± 9.0 23.7 ± 11.1 0.4 ± 4.9 21.3 ± 7.7 21.3 ± 7.5 0.1 ± 9.3 0.85
Total cholesterol (mg/dL) 165.5 ± 29.5 159.9 ± 32.9 5.6 ± 31.9 163.2 ± 36.7 157.5 ± 34.1 5.7 ± 34.6 0.99
LDL-cholesterol (mg/dL) 101.7 ± 28.1 94.4 ± 30.2 7.3 ± 28.8 99.7 ± 32.0 94.6 ± 31.1 5.1 ± 28.4 0.76
HDL-cholesterol (mg/dL) 40.5 ± 8.3 41.9 ± 9.0 1.4 ± 5.6 42.1 ± 7.5 41.5 ± 8.1 0.6 ± 3.0 0.10
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; HOMA-B, homeostasis model of assessment-
estimated B cell function; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check index; TAC, total
antioxidant capacity; UPDRS, uniﬁed Parkinson's disease rating stage.
a Data are means± SDs.
b P values represent the time  group interaction (computed by analysis of the one-way repeated measures ANOVA).
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cell death induced by 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) in bilateral rat model of PD. In addi-
tion, the inﬂuence of DHA on brain-derived neurotrophic factor
(BDNF) levels has reported in the hippocampus, cerebral cortex
(Vines et al., 2012) and spinal cord (Ying et al., 2012). In another
study, using the MPTP-induced experimental PD model, vitamin E
deﬁcient mice were much more susceptible to MPTP toxicity than
control mice (Odunze et al., 1990). However, a-tocopherol did not
prevent the marked striatal dopamine depletions produced by
MPTP (Martinovits et al., 1986). Omega-3 intake may improve
neuronal survival through facilitating membrane translocation/
activation of Akt and a downstream effector in the phosphoinosi-
tide 3-kinase (PI3K) pathway (Akbar et al., 2005). Vitamin E intake
may have protective effect on dopamine-induced cell death and
ROS production (Storch et al., 2000), which in turnwould result in a
control over neurological symptoms in people with PD.
This intervention demonstrated that omega-3 and vitamin E co-
supplementation in subjects with PD for 12weeks decreased serumhs-CRP, and increased plasma TAC and GSH levels, while unchanged
plasmaNO andMDA levels. Our previous study in GDMwomenwas
demonstrated that co-administration with 1000 mg omega-3 fatty
acids and 400 IU vitamin E daily for 6 weeks elevated TAC and NO,
and decreased MDA values, but did not inﬂuence plasma GSH and
serum hs-CRP (Jamilian et al., 2016). In line with our results, taking
omega-3 in subjects with systemic lupus erythematosus for 12
weeks decreased CRP concentrations (Borges et al., 2016). In a
meta-analysis study, it was reported that vitamin E intake
decreased serum CRP concentrations (Saboori et al., 2015). Unlike,
supplementation with 1400 mg of EPA þ DHA for 18 weeks did not
reduce indices of systemic inﬂammation in healthy adults
(Muldoon et al., 2016). In addition, no signiﬁcant effect in TAC
values was seen after intake of a combined dietary supplementa-
tion containing omega-3 fatty acids, vitamin E, B3 and gamma-
oryzanol among dyslipidemic subjects (Accinni et al., 2006). Pre-
vious studies have shown that signs of oxidative and nitrosative
stress (O&NS) were observed in the peripheral blood of PD patients,
including increased lipid hydroperoxides, higher levels of by-
Table 3
Adjusted changes in uniﬁed Parkinson's disease rating stage, biomarkers of inﬂammation and oxidative stress, and metabolic proﬁles in patients with Parkinson's disease
that received either omega-3 fatty acids plus vitamin E or placebo.a
Placebo group
(n ¼ 30)
Omega-3 and vitamin E group
(n ¼ 30)
Pb
UPDRS total (0e195) 4.7 ± 2.0 3.4 ± 2.0 0.005
hs-CRP (mg/mL) 0.3 ± 0.1 0.3 ± 0.1 <0.001
NO (mmol/L) 3.6 ± 0.9 4.3 ± 0.9 0.60
TAC (mmol/L) 6.8 ± 12.4 74.4 ± 12.5 0.001
GSH (mmol/L) 17.4 ± 11.5 39.2 ± 11.5 0.001
MDA (mmol/L) 0.02 ± 0.04 0.14 ± 0.04 0.02
FPG (mg/dL) 1.9 ± 3.3 10.6 ± 3.3 0.07
Insulin (mIU/mL) 1.1 ± 0.8 1.8 ± 0.8 0.01
HOMA-IR 0.3 ± 0.2 0.7 ± 0.2 0.005
HOMA-B 4.5 ± 3.2 4.7 ± 3.2 0.04
QUICKI 0.006 ± 0.005 0.008 ± 0.005 0.05
Triglycerides (mg/dL) 3.0 ± 6.7 0.6 ± 6.7 0.70
VLDL-cholesterol (mg/dL) 0.6 ± 1.3 0.1 ± 1.3 0.70
Total cholesterol (mg/dL) 5.5 ± 5.3 5.7 ± 5.3 0.97
LDL-cholesterol (mg/dL) 7.2 ± 4.8 5.2 ± 4.8 0.76
HDL-cholesterol (mg/dL) 1.2 ± 0.8 0.4 ± 0.8 0.16
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; HOMA-B, homeostasis model of
assessment-estimated B cell function; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity check
index; TAC, total antioxidant capacity; UPDRS, uniﬁed Parkinson's disease rating stage.
a All values are means± SEs.
b Obtained from analysis of ANCOVA adjusted for baseline values þ age and baseline BMI.
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Farias et al., 2016). As MDA is a highly signiﬁcant biomarker of PD
per se, changes in lipid hydroperoxides are more associated with
disease progression (Baillet et al., 2010). Few studies have reported
that lipid peroxidationwith the formation of neoepitopes like MDA
is a key phenomenon of PD that further drives adaptive changes in
superoxide dismutase (SOD) and catalase (CAT) activity (Cheng
et al., 2016; de Farias et al., 2016). In addition, higher concentra-
tions of plasma NO can nitrosylate proteins thereby modifying the
activity of many proteins related to intracellular signaling and im-
mune responses. This explains that NO generated by inducible ni-
tric oxide synthase (iNOS) may result in inﬂammatory responses
and apoptosis. In PD patients, the injury to dopaminergic neurons
promotes microglial activation, upregulation of iNOS and increased
NO production (Moylan et al., 2014). The absence of signiﬁcant
effect of omega-3 and vitamin E co-supplementation on plasma NO
andMDA levels in the current studymight bemediated by different
study designs, the source of omega-3 and vitamin E, dosage of
omega-3 and vitamin E as well as duration of the study. Neuro-
inﬂammation due to increased biomarkers of inﬂammation and
oxidative stress is considered a major factor promoting the path-
ogenesis of PD (Yu et al., 2016). Inﬂammation both peripheral and
neuroinﬂammation may lead to immune responses in the brain
(Phani et al., 2012). Then, the immune response in the brain leads to
microglial activation, elaboration of pro-inﬂammatory cytokines,
the production of ROS (Wypijewska et al., 2010), pigment formation
(Double, 2012), and secondary neuronal injury (Shi et al., 2010).
Omega-3 and vitamin E directly decrease the production of in-
ﬂammatory cytokines in liver (Devaraj and Jialal, 1998; Li et al.,
2005). Furthermore, omega-3 fatty acids and vitamin E may
decrease inﬂammation and oxidative stress through inhibiting
activation of nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-кB) (Rossi et al., 2000;Wu et al., 2004) and activity
increase of protein phosphatase 2A (Nakamura et al., 1998).
We found shown that omega-3 and vitamin E co-
supplementation in subjects with PD for 12 weeks decreased
serum insulin values, HOMA-IR, HOMA-B, and increased QUICKI,
but it did not affect FPG and lipid fractions. We have previously
shown that omega-3 plus vitamin E intake in patients with GDM for
6 weeks had beneﬁcial effects on glucose metabolism, serumtriglycerides, VLDL-cholesterol, and HDL-cholesterol values, but
unaltered other lipid proﬁles (Taghizadeh et al., 2016). In a study
conducted by Hutchins et al. (2013) it was observed that ﬂaxseed
oil intake in overweight or obese people with pre-diabetes for 3
months led to a signiﬁcant reduction in insulin and a signiﬁcant
elevation in insulin sensitivity. In another study, a signiﬁcant
reduction in HOMA-IR was also observed following intake of
vitamin E at a dosage of 600 mg/day in obese children with non-
alcoholic fatty liver disease for 6 months (D'Adamo et al., 2013).
However, taking ﬂaxseed oil among patients with T2DM for 180
days did not affect glucose metabolism and lipid proﬁles (Zheng
et al., 2016). In addition, high-dose vitamin E intake (1200 IU/
day) in subjects with diabetic nephropathy (DN) for 12 weeks did
not inﬂuence glucose metabolism (Khatami et al., 2016). Early re-
ports previously have shown that up to 50e80% of subjects with PD
have glucose intolerance (Sandyk, 1993), however data from more
contemporary prospective studies suggest the relation is more
modest with T2DM subjects having approximately a 40% increased
risk of developing PD (Driver et al., 2008). Abnormal insulin
signaling and insulin resistance in patients with PD may be linked
with extracellular events of relevance to neurodegeneration and
inﬂammation, which in turn is increasingly recognised as a main
contributor to the pathogenesis of PD (Athauda and Foltynie, 2016).
Therefore, joint omega-3 fatty acids and vitamin E supplements
due to their useful effects on glycemic control may be useful to
control neurological symptoms in patients with PD. Omega-3 fatty
acids plus vitamin E intake might improve markers of insulin
metabolism through stimulating AMP-activated protein kinase
(AMPK) in the muscle (Yamauchi et al., 2002) and inhibiting acti-
vation of NF-kB (Altavilla et al., 2000).
This research had few limitations. Firstly, due to budget limita-
tions, we did not evaluate measurements of fatty acids proﬁles and
vitamin E levels at baseline and the after 12-week intervention. We
did not evaluate the relative contribution of omega-3 fatty acids
and vitamin E in the outcomes. One want conclude that the treat-
ment effects observed in the current study was due to the effect of
omega-3 fatty acids or vitamin E supplements. Therefore, further
studies are needed with single supplements compared with co-
supplements used in the current study in order to assess beneﬁ-
cial effects on UPDRS and metabolic proﬁles in PD patients. In
M. Taghizadeh et al. / Neurochemistry International 108 (2017) 183e189188addition, we did not evaluate other biomarkers of inﬂammation
and oxidative stress.
5. Conclusions
Overall, our study demonstrated that omega-3 fatty acids and
vitamin E co-supplementation in people with PD had favorable
effects on UPDRS, hs-CRP, TAC, GSH and markers of insulin meta-
bolism, whereas it did not affect other biomarkers of inﬂammation
and oxidative stress, and lipid proﬁles.
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